Atlas Trials

Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

10 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

RecordFirmDate
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma (NCT04848064)John Reneau2022-05-06
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas (NCT03373305)City of Hope Medical Center2019-03-01
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741)Mayo Clinic2018-03-27
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma (NCT03409432)John Reneau2018-03-16
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin (NCT03278782)M.D. Anderson Cancer Center2017-11-14
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625)National Cancer Institute (NCI)2017-09-27
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820)Mayo Clinic2017-04-04
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533)National Cancer Institute (NCI)2012-08-03

Track Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.